Prescription drug spending
The impact of age and chronic disease status
Dados Bibliográficos
| ID | 11019001 |
|---|---|
| Autores | C Mueller (0000-0002-3369-9124), Curt D Mueller (Project HOPE), Claudia L Schur (0000-0002-8358-2434), C Schur, Joan O’connell (0000-0003-3498-1153) |
| Ano | 1997 |
| Volume | 87 |
| Fascículo | 10 |
| Páginas | 1626-1629 |
| Data de publicação | 1997-10-01 |
| Peer Reviewed | Sim |
| Open Access | Não |
| Tipo | ARTICLE |
| Periódico | American Journal of Public Health (JOURNAL) |
| Identificadores do periódico | ISSN: 0090-0036 • E-ISSN: 1541-0048 |
| Editora | American Public Health Association (PUBLISHER • US) |
| DOI | 10.2105/ajph.87.10.1626 |
| PMID | 9357343 |
| OpenAlex | W2086606120 |
| Idioma | EN |
| Citações recebidas | 9 |
| Referências citadas | 5 |
OBJECTIVES: The purpose of this study was to examine how pharmaceutical expenditures vary by age and the presence of chronic health problems. METHODS: Data from the 1987 National Medical Expenditure Survey were used to obtain nationally representative estimates of outpatient prescription drug expenditures for the noninstitutionalized population and the fraction of total health expenditures used to purchase medications for age-chronic disease population subgroups. RESULTS: Although the elderly make up 12% of the population, they account for 34% of total pharmaceutical expenditures. Pharmaceutical expenditures are 9% of total expenditures for children, 13% for nonelderly adults, and 23% for the elderly. Among nonelderly adults, approximately one third have at least one chronic condition and account for over two thirds of drug expenditures. Among the elderly, 36% have three or more chronic conditions and account for 57% of drug expenditures for this group; 41% of total drug expenditures are for cardiovascular or renal drugs. CONCLUSIONS: Significant pharmaceutical spending is for treatment of chronic conditions, which subjects insurance coverage to adverse selection and could affect the design of prescription drug benefit packages. Current enrollees in Medicare risk management plans who have drug benefits may face significantly higher out-of-pocket expenses for pharmaceuticals if capitation rates are cut as a means of controlling Medicare program expenditures
Chronic disease · Drug · Environmental health · Family medicine · Health care · Health insurance · Medical Expenditure Panel Survey · Medical prescription · Population · Prescription drug · Psychiatry · Health Systems, Economic Evaluations, Quality of Life · Medication Adherence and Compliance · Medicine · Pharmaceutical Economics and Policy · Pharmacology
Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies
The global burden of multiple chronic conditions
Clustering and Healthcare Costs With Multiple Chronic Conditions in a US Study
Assessing the effect of health status on multidimensional poverty among older adults
Reducing Obesity Among People With Disabilities
Prescription Noncompliance due to Cost Among Adults With Disabilities in the United States
Health Insurance Status, Cost-Related Medication Underuse, and Outcomes Among Diabetes Patients in Three Systems of Care
Impending widowhood and health care spending
Composição dos gastos privados com medicamentos utilizados por aposentados e pensionistas com idade igual ou superior a 60 anos em Belo Horizonte, Minas Gerais, Brasil
| Obras citantes distintas | 9 |
|---|---|
| Citações por ano | 0,38 |
| Intervalo de citações | 2002 - 2023 (22) |
| Velocidade de citação | historical |
| Altamente citado | Não |
| Tipos de citação | Neutras: 8 |